FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048631764> ?p ?o ?g. }

• W3048631764 endingPage "1409" @default.
• W3048631764 startingPage "1405" @default.
• W3048631764 abstract "Abstract Introduction In the last years, many new drugs have been developed targeting different oncology pathways, overall improving both quality of life and survival in several malignancies. However, the increase of those therapies is associated with novel toxicities, mainly immune-related adverse events (irAEs), never observed before. Different irAEs are now well characterized, and, among them, neuromuscular complications, following immune checkpoint inhibitor (ICPi) therapy, are increasingly studied and described. However, there are also neurological complications related to the use of other targeted therapies, less known and probably underestimated. Herein we describe two oncological patients who developed neuromuscular diseases after administration of targeted therapies, different from ICPi. Case reports The first patient was treated with the combination of Vemurafenib and Cobimetinib, BRAF and MEK inhibitors, respectively, for a cutaneous melanoma. One year after the beginning of the combined treatment, she developed a sub-acute motor neuropathy with predominant cranial nerve involvement. She was successfully treated with methylprednisolone. The second patient received therapy with Imatinib, tyrosine kinase inhibitor and precursor of the targeted therapy, for a gastrointestinal stromal tumour. Few days after the first administration, he developed generalized myasthenia gravis with respiratory failure. Clinical remission was obtained with plasma-exchange, intravenous immunoglobulins and steroids. Discussion and Conclusion We strengthen the relevance of neuromuscular complications which may occur long after treatment start or in patients receiving not only the latest ICPi but also “older” and apparently better-known targeted therapies. Also in the latter cases, an immune-mediated “off-target” pathogenic mechanism can be hypothesized, and consequences can be life threatening, if not promptly diagnosed and appropriately managed." @default.
• W3048631764 created "2020-08-18" @default.
• W3048631764 creator A5010840428 @default.
• W3048631764 creator A5020120126 @default.
• W3048631764 creator A5040264603 @default.
• W3048631764 creator A5048673781 @default.
• W3048631764 creator A5049829315 @default.
• W3048631764 creator A5056147326 @default.
• W3048631764 creator A5057878321 @default.
• W3048631764 creator A5069322473 @default.
• W3048631764 creator A5071929183 @default.
• W3048631764 creator A5072450840 @default.
• W3048631764 creator A5076110819 @default.
• W3048631764 creator A5089112034 @default.
• W3048631764 date "2020-08-11" @default.
• W3048631764 modified "2023-09-26" @default.
• W3048631764 title "Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature" @default.
• W3048631764 cites W1979036864 @default.
• W3048631764 cites W2022053622 @default.
• W3048631764 cites W2032331743 @default.
• W3048631764 cites W2103675014 @default.
• W3048631764 cites W2111404068 @default.
• W3048631764 cites W2312894731 @default.
• W3048631764 cites W2578547225 @default.
• W3048631764 cites W2591909501 @default.
• W3048631764 cites W2605725094 @default.
• W3048631764 cites W2741336470 @default.
• W3048631764 cites W2805130256 @default.
• W3048631764 cites W2890965651 @default.
• W3048631764 cites W2892221543 @default.
• W3048631764 cites W2902353061 @default.
• W3048631764 cites W2979167002 @default.
• W3048631764 cites W2988124258 @default.
• W3048631764 cites W2808174600 @default.
• W3048631764 doi "https://doi.org/10.1007/s10072-020-04604-1" @default.
• W3048631764 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7955989" @default.
• W3048631764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32783159" @default.
• W3048631764 hasPublicationYear "2020" @default.
• W3048631764 type Work @default.
• W3048631764 sameAs 3048631764 @default.
• W3048631764 citedByCount "5" @default.
• W3048631764 countsByYear W30486317642021 @default.
• W3048631764 countsByYear W30486317642022 @default.
• W3048631764 crossrefType "journal-article" @default.
• W3048631764 hasAuthorship W3048631764A5010840428 @default.
• W3048631764 hasAuthorship W3048631764A5020120126 @default.
• W3048631764 hasAuthorship W3048631764A5040264603 @default.
• W3048631764 hasAuthorship W3048631764A5048673781 @default.
• W3048631764 hasAuthorship W3048631764A5049829315 @default.
• W3048631764 hasAuthorship W3048631764A5056147326 @default.
• W3048631764 hasAuthorship W3048631764A5057878321 @default.
• W3048631764 hasAuthorship W3048631764A5069322473 @default.
• W3048631764 hasAuthorship W3048631764A5071929183 @default.
• W3048631764 hasAuthorship W3048631764A5072450840 @default.
• W3048631764 hasAuthorship W3048631764A5076110819 @default.
• W3048631764 hasAuthorship W3048631764A5089112034 @default.
• W3048631764 hasBestOaLocation W30486317641 @default.
• W3048631764 hasConcept C118552586 @default.
• W3048631764 hasConcept C121608353 @default.
• W3048631764 hasConcept C126322002 @default.
• W3048631764 hasConcept C143998085 @default.
• W3048631764 hasConcept C16568411 @default.
• W3048631764 hasConcept C197934379 @default.
• W3048631764 hasConcept C2776131300 @default.
• W3048631764 hasConcept C2777701055 @default.
• W3048631764 hasConcept C2778105408 @default.
• W3048631764 hasConcept C2779615886 @default.
• W3048631764 hasConcept C2781230642 @default.
• W3048631764 hasConcept C2781433595 @default.
• W3048631764 hasConcept C2994587330 @default.
• W3048631764 hasConcept C71924100 @default.
• W3048631764 hasConceptScore W3048631764C118552586 @default.
• W3048631764 hasConceptScore W3048631764C121608353 @default.
• W3048631764 hasConceptScore W3048631764C126322002 @default.
• W3048631764 hasConceptScore W3048631764C143998085 @default.
• W3048631764 hasConceptScore W3048631764C16568411 @default.
• W3048631764 hasConceptScore W3048631764C197934379 @default.
• W3048631764 hasConceptScore W3048631764C2776131300 @default.
• W3048631764 hasConceptScore W3048631764C2777701055 @default.
• W3048631764 hasConceptScore W3048631764C2778105408 @default.
• W3048631764 hasConceptScore W3048631764C2779615886 @default.
• W3048631764 hasConceptScore W3048631764C2781230642 @default.
• W3048631764 hasConceptScore W3048631764C2781433595 @default.
• W3048631764 hasConceptScore W3048631764C2994587330 @default.
• W3048631764 hasConceptScore W3048631764C71924100 @default.
• W3048631764 hasFunder F4320322794 @default.
• W3048631764 hasIssue "4" @default.
• W3048631764 hasLocation W30486317641 @default.
• W3048631764 hasLocation W30486317642 @default.
• W3048631764 hasOpenAccess W3048631764 @default.
• W3048631764 hasPrimaryLocation W30486317641 @default.
• W3048631764 hasRelatedWork W2147630681 @default.
• W3048631764 hasRelatedWork W2158981694 @default.
• W3048631764 hasRelatedWork W2214943066 @default.
• W3048631764 hasRelatedWork W2289338532 @default.
• W3048631764 hasRelatedWork W2791158187 @default.
• W3048631764 hasRelatedWork W3029766637 @default.
• W3048631764 hasRelatedWork W3037517363 @default.

• next